How Stem Cell Therapy for Parkinson's Works

The Disease That Steals Movement

Parkinson's disease affects more than 11 million people worldwide, making it the fastest-growing neurodegenerative condition on the planet. Its prevalence has doubled in the past 25 years and shows no sign of slowing. At its core, Parkinson's is a disease of loss — specifically, the progressive death of a small cluster of neurons deep in the brain that produce the chemical messenger dopamine.

Dopamine is essential for smooth, coordinated movement. As dopamine-producing neurons die off, patients develop the hallmark symptoms of Parkinson's: tremor, muscle rigidity, slow movement, and impaired balance. Eventually, the disease also affects cognition, sleep, and mood.

Why Current Treatments Fall Short

For decades, the gold-standard treatment has been levodopa, a drug that the brain converts into dopamine. It works remarkably well — at first. In the early and middle stages of the disease, levodopa can restore near-normal movement. But it does not stop the underlying neurodegeneration. As more neurons die, the drug becomes harder to calibrate, and patients begin to experience unpredictable swings between mobility and paralysis, as well as painful involuntary movements called dyskinesias.

No existing medication replaces the neurons themselves. That is precisely what stem cell therapy aims to do.

What Are Stem Cells?

Stem cells are biological building blocks — unspecialized cells that can develop into many different cell types given the right chemical signals. For Parkinson's research, two types have been particularly important:

• Embryonic stem cells (hESCs): Derived from early human embryos, these are highly versatile but carry ethical concerns and immune rejection risks.
• Induced pluripotent stem cells (iPSCs): Created by reprogramming adult cells — typically from skin or blood — back into an embryonic-like state. iPSCs can come from donor banks, sidestepping some ethical concerns and potentially allowing for better immune matching.

In both cases, scientists then coax these stem cells in the laboratory to become dopaminergic progenitor cells — the precursors to dopamine-producing neurons. This involves activating specific molecular pathways, including the WNT signaling pathway, to push the cells toward a midbrain identity — the same region where Parkinson's damage occurs.

How the Transplant Works

Once researchers have produced millions of dopaminergic progenitors, surgeons inject them directly into the putamen, a region of the brain that plays a central role in movement control. The hope is that transplanted cells will survive, mature into functional neurons, form connections, and begin producing dopamine — effectively rebuilding what the disease has destroyed.

This concept is not new. Experimental fetal-tissue transplants in the 1980s and 1990s showed it was biologically possible for transplanted dopamine cells to survive and function in the human brain. But fetal tissue is ethically fraught, scarce, and highly variable. Stem cells offer a scalable, more consistent alternative.

What the Clinical Trials Show

In a landmark Phase I/II trial at Kyoto University Hospital, seven Parkinson's patients received bilateral iPSC-derived dopaminergic cell transplants. After 24 months of follow-up, researchers reported that the transplanted cells survived, produced dopamine, and — critically — did not form tumors. Four of the six fully evaluated patients showed measurable clinical benefit when off their medication, and five showed benefit when on medication. Brain scans revealed an average 44.7% increase in dopamine activity in the transplanted area, with higher doses producing larger gains.

A parallel trial using embryonic stem cell-derived neurons at Memorial Sloan Kettering Cancer Center in the United States enrolled 12 patients, with early results also showing signs of cell survival and functional benefit, according to a Nature report.

The World's First Approval

In early 2026, Japan became the first country to grant conditional regulatory approval to a stem cell therapy for Parkinson's disease. The treatment, called raguneprocel (brand name Amchepry), was developed by Sumitomo Pharma and is restricted to eligible patients within the Japanese healthcare system. Conditional approval means the therapy can reach patients while longer-term efficacy data continues to be collected — a framework Japan has used to accelerate access to regenerative medicines.

Challenges That Remain

Stem cell therapy for Parkinson's is not yet a cure, and significant hurdles remain. The surgical procedure is invasive, and patient selection is carefully restricted. The trials so far are small, and longer follow-up is needed to determine how durable the benefits are and whether repeat transplants will be necessary as the disease progresses. Cost and global access are also concerns: a manufacturing process that produces clinical-grade neurons at scale remains technically demanding.

Researchers are also investigating whether personalized iPSCs — derived from the patient's own cells — might reduce immune rejection, though donor-bank approaches may ultimately prove more practical for widespread use.

Why It Matters

For the first time in the history of Parkinson's treatment, a therapy has moved from concept to approval that replaces lost neurons rather than merely compensating for them. If larger trials confirm the early results and manufacturing becomes more accessible, stem cell therapy could mark a fundamental shift in how one of the world's most common neurodegenerative diseases is treated — not just managed, but potentially repaired.